Go to deals
Healthcare

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.

PanTera, an IBA and SCK CEN joint venture, aims to secure the large-scale production of actinium-225 (225Ac), which is one of the most promising alpha-emitting radioisotopes to fight cancer. The funds raised will be used primarily toward the construction of a state-of-the-art production facility in Belgium. This facility will not only enable large-scale production, it will also help fulfill PanTera’s ultimate goal to improve the accessibility of future, innovative cancer therapy based on 225Ac and theranostics.

Oaklins’ team in Belgium acted as the sole financial advisor in this transaction.

Talk to the deal team

Cédric Michils

Managing Director
Brussels, Belgium
Oaklins KBC Securities

Bart Delusinne

Managing Director
Brussels, Belgium
Oaklins KBC Securities

Nicolas Lambers

Associate Director
Brussels, Belgium
Oaklins KBC Securities

Michaël Rixhon

Associate Director
Brussels, Belgium
Oaklins KBC Securities

Robin Bundervoet

Associate
Brussels, Belgium
Oaklins KBC Securities

Related deals

Cerbios-Pharma has been acquired by HAS Healthcare
Healthcare

Cerbios-Pharma has been acquired by HAS Healthcare

Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.

Learn more
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Healthcare

Pharma-Skan & Skan-Medic have been acquired by Brygge Partners

Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.

Learn more
The Canton of Solothurn had a valuation report prepared for its hospitals
Healthcare

The Canton of Solothurn had a valuation report prepared for its hospitals

The Canton of Solothurn is the owner of Solothurner Spitäler AG (soH), with its three hospitals in Solothurn, Olten and Dornach.

Learn more